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Abstract 
The determination of α-keto acids has clinical importance, because these are intermediates in a 
number of biochemical processes. This work reports the development of an HPLC procedure for 
the  analysis  α-keto  acids  in  blood  and  urine  samples  after  derivatization  with  4-nitro-1,2-
phenylenediamine  (NPD).  Nine  α-keto  acids:  glyoxylic  acid  (GA),  pyruvic  acid  (PYR),  2-
oxobutyric  acid  (KB),  3-methyl-2-oxobutyric  acid  (MKBA),  3-methyl-2-oxovaleric  acid 
(K3MVA), 2-oxoglutaric acid (KG), 4-methyl-2-oxovaleric acid (K4MVA), 2-oxohexanoic acid 
(KHA) and phenylpyruvic acid (PPY)  were derivatized with (NPD) at  pH 3 and separated on a 
Zorbax 300 SB-C18 HPLC column (4.6x150mm id) and photodiode array detection at 255 nm. 
The isocratic elution was performed with methanol: water: acetonitrile (42: 56:2, v/ v/ v) with a 
flow rate 0.9 mL/min. The keto acids separated within 14 min. The method was repeatable with a 
relative standard deviation (RSD) of 0.1-2.9% for each of the α-keto acids. The limits of detection 
and  quantitation  were  obtained  within  the  range  0.05-0.26  µg/  mL  and  0.15-0.8  µg/  mL 
respectively. The method was applied for determination of α-keto acids from a pharmaceutical 
preparation, human  serum  and  urine  samples  of  healthy  volunteers  and  diabetic  patients.  The 
results were further confirmed by standard addition technique. The method is rapid and simple and 
is suitable for the separation and determination of α-keto acids from clinical samples. 
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Introduction 
 
α-Keto acids are key intermediates in a number of 
major biochemical pathways including glycolysis, 
amino  acids  and  carbohydrate  metabolism  [1]. 
Each  of  the  keto  acid  has  its  specific  function. 
Pyruvic acid (PYR) is involved in the biosynthesis 
of alanine [2], and branched chain keto acids: 3-
methyl-2-oxovaleric acid (K3MVA) and 4-methyl-
2-oxovaleric  acid  (K4MVA)  can  regulate  protein 
turn over [3, 5]. The determination of the -keto 
acids is of interest for pathological conditions such 
as  sepsis  [6],  burns  [7]  and  heptic  disorders  [8]. 
The concentration of phenylpyruvic acid increases 
in the serum of patients with hereditary metabolic 
diseases [9].  A higher risk of infections diseases 
have been reported in  elderly people, because  of 
protein  malnutrition  and  decline  in  the  immune 
system  [10].  The  subjects  may  improve  on 
supplementation with α-keto acids. Therefore, the 
determination of α-keto acids in biological fluids is 
of considerable interest and relevance.  
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A  number  of  analytical  methods  for  the 
determination  of  α-keto  acids  are  based  on  gas 
chromatography  (GC-FID,  GC-MSD)  [11,  19], 
high performance liquid chromatography (HPLC) 
[20, 27] and capillary zone electrophoresis (CZE) 
[28].  Several  derivatizing  reagents  have  been 
reported  for  the  HPLC  determination  of  -keto 
acids  with  spectrophotometric  and 
spectrofluorimetric  detection.  Among  these 
frequently  used  reagents  are  2,4-dinitro-
phenylhydrazine  [29-30],  4-hydrazine-2-
stilbanzole [31], o-phenylenediamine [32, 33], 1,2-
diamino-4,5-dimethoxybenzene [34], 1,2-diamino-
4,5-methylenedioxybenzene  [35]  and  4,5-
diaminophthalhydrazide  [36].  4-nitro1,  2-
phenylenediamine  (NPD)  is  related  to  o-
phenylenediamine  and  has  been  used  for  the 
determination  of  -keto  acids  by  paper 
chromatography [37, 39]. However, many of these 
techniques  are  time-consuming  and  involving 
extensive  sample  preparation.  The  present  work 
was aimed at developing a rapid HPLC method for 
the  analysis  of  -keto  acids,  using  4-nitro-1,2-
phenylenediamine  (NPD)  as  derivatizing  reagent 
from a pharmaceutical preparation, human serum 
and  urine  of  healthy  volunteers  and  diabetic 
patients.  
 
Materials and Methods 
Chemicals and Reagents 
 
GA  monohydrate,  PYR,  KB,  MKBA, 
KHA,  K3MVA,  K4MVA,  sodium  salt,  KG 
monosodium  salt,  NPD  (Fluka,  Switzerland),      
and  PPY  (sigma,  USA)  were  used.  The       
standard  solutions  of  α-Keto  acids  (1.0  mg/mL) 
were  prepared  in  10  %  acetic  acid  (w/v).      
Further  solutions  were  prepared  by  appropriate 
dilution.  
 
The  NPD  was  recrystalized  from  n-
heptane  before  use.  Methanol  (Fisher  Scientific, 
HPLC  grade,  Leicestershire,  UK),  acetic  acid, 
(Riedel-dehaen,Germany),  hydrochloric  acid 
(37%),  potassium  chloride,  sodium  acetate, 
ammonium acetate, boric acid, sodium tetraborate, 
sodium bicarbonate, sodium carbonate, ammonium 
chloride and ammonia (25%) (E. Merck, Germany) 
were used. Freshly prepared double distilled water 
was used throughout the study. 
 
The  Buffer  solutions  within  pH  1-10  at 
unit  interval  were  prepared  from  Hydrochloric   
acid (0.1 M) and potassium chloride (1 M) (pH 1- 
2),  acetic  acid  (1  M)  and  sodium  acetate  (1  M)   
(pH 3-6), ammonium acetate  (1 M) (pH7), boric 
acid (1 M) and sodium tetra borate (1 M) (pH-8 ), 
sodium  bicarbonate  (1  M),  sodium  carbonate 
(saturated) (pH-9) and ammonium chloride (1 M) 
and ammonia solution (1 M) (pH-10).   
 
All  pH  measurements  were  made  with 
Orion 420 A pH meter (Orion (Pvt.), Ltd, Boston, 
U.S.A) with combined glass electrode and internal 
reference electrode. Spectrophotometric study was 
carried  out  with  a  double-beam  Hitachi  220 
Spectrophotometer  (Hitachi  (Pvt)  Ltd  Tokyo, 
Japan) with dual 1 cm silica cuvettes.  
 
Analytical Procedures 
Spectrophotometric Procedure 
 
To the solution (1-2 mL) containing (5-100 
µg)  GA,  PYR,  KB,  MKBA,  K3MVA,  KG, 
K4MVA, KHA, and PPY was transferred to 10 mL 
volumetric  flask  separately.  Each  of  the  solution 
was added NPD solution (1.5 mL, 1.0 %, w/v in 
methanol), acetic acid sodium acetate buffer (pH 3) 
(1 mL) and contents were warmed on water bath at 
80 
0C for 30 min. The volume was adjusted with 
methanol and absorption spectrum was recorded in 
the spectral range of 400-250 nm against reagent 
blank. The reagent blank was prepared following 
the same procedure, without the addition of α- keto 
acids. 
 
HPLC Procedure 
   
To an aqueous solution (1mL) containing 
GA,  PYR,  MKBA,  KB,  K3MVA,  KG,       
K4MVA,  KHA,  and    PPY    of  each  within  the 
concentration  range  as  indicated  in  (Table  1),     
was added NPD reagent solution (1 mL, 1%, w/ v 
in  methanol)  and  acetic  acid-sodium  acetate    
buffer pH  3 (1 mL). The contents  were  warmed   
at  80 
0C  for  30  min  and  volume  was  adjusted     
with  methanol  to  10  mL.  The  solution  (20  µl)    
was  injected  on  the  column  and  eluted  with 
methanol:  water:  acetonitrile  (42:  56:  2  v/  v/  v) 
with a flow rate 0.9 mL/ min. The detection was 
set at 255 nm.  
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Table 1. HPLC parameter for α-Keto acids using NPD as a derivatization reagent 
 
Sr. 
No. 
Name of 
Compound 
Calibration 
Range 
(µg/mL) 
Coefficient of 
determination 
(R
2 
Least Square 
Or Regression 
Limit of 
Detection 
N ( LOD) 
(µg/mL) 
Limit of 
Quantitation 
(LOQ) 
1  GA  (0.2-5)  0.9968  Y=5.0029x+ 
0.0095 
0.06  0.2 
2  PYR  (0.2-20)  0.9978  Y=3.1505x+ 
0.0286 
0.05  0.15 
3  KB  (0.3-100)  0.9986  Y=0.3676x+ 
0.0381 
0.13  0.39 
4  MKBA 
 
(0.45-100)  0.998  Y=0.4897x+ 
0.0119 
0.15  0.45 
5  K3MVA  (0.6-100)  0.9976  Y=0.2584x+ 
0.0286 
0.266  0.8 
6  KG  (0.5-100)  0.9988  Y=0.1137x+ 
0.0333 
0.16  0.5 
7  K4MVA  (0.6-100)  0.9983  Y=0.148x+ 
0.0333 
0.2  0.6 
8  KHA  (0.7-100)  0.9953  Y=0.1265x+ 
0.001 
0.25  0.75 
9  PPY  (0.4-100)  0.9957  Y=0.1196x-
0.0519 
0.1  0.3 
 
 
Chromatographic Conditions 
 
HPLC  was  carried  out  on  Agilent      
model  1100–network  HPLC  System            
(Agilent  Technology  Inc,  USA)  1100  series  a 
syringe  loading  sample  injector  containing  a        
20  µL  loop,  two  quart  pump  G1311A,        
Degasser  G1379A  with  DAD  G1315B        
detection  system.  The  computer  with  Chem     
Station  software  controlled  the  HPLC.               
The  column  ZORBAX  300  SB-C18                    
(4.6  x  150  mm  i.d.)  (Agilent  Technology  Inc, 
USA)  was  used  throughout  the  study.  Retention 
times and peak areas were determined by enhanced 
integrator.  
                           
Analysis of Pharmaceutical preparation 
   
Five  tablets  Ketostril  (Fresenius  Kabi    
Bad  Homburg,  Germany)  were  ground  to      
powder  and  amount  (0.802  g)  corresponding         
to  one  tablet  was  dissolved  in  10%                    
acetic  acid  (20  mL).  The  solution  was            
filtered  and  volume  adjusted  to  100  mL.  Well 
mixed  solution  0.4  mL  and  0.6  mL  were 
transferred  to  10  mL  volumetric  flasks  and     
HPLC  analytical  procedure  was  followed.  The 
quantitation  was  carried  out  using  external 
calibration curve.   
  
Analysis  of  Pharmaceutical  Preparation  by 
Standard Addition  
 
Five  tablets  of  Ketostril  were  treated  as 
Analysis  of  Pharmaceutical  preparation.  The 
solutions  0.4  mL  and  0.6  mL  were  taken  in 
duplicate.  A  solution  was  processed  as  HPLC 
analytical procedure and others were added MKBA 
50 µg, K3MVA 60 µg, and K4MVA 100 µg, PPY 
40  µg,  and  again  processed  as  HPLC  analytical 
procedure. The quantitation was carried out from 
external  calibration  curve  and  an  increase  in  the 
response with added standards. 
 
Sample Collection and Pretreatment 
 
The  blood  and  urine  samples  of  diabetic 
patients with verbal contents were obtained from 
LUMHS  Hospital,  Jamshoro.  The  blood  samples 
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syringe.  Urine  samples  were  collected  in  the 
morning in clean plastic bottle. The blood glucose 
level of the patient was collected from the record 
of the hospital of the patient on the day of sample 
collection. The data was collected with permission 
of duty doctor and the patients. The blood samples 
of  healthy  volunteers  with  verbal  consent  were 
collected  from  Dr.  M.  A.  Kazi  Institute  of 
Chemistry  and  their  blood  glucose  level  were 
determined by Micro-lab (E-Merck, Germany).  
 
Determination of α-Keto Acids from Serum 
 
The blood samples (5 mL) collected from 
healthy  volunteers  and  diabetic  patients  were 
allowed  at  room  temperature  for  1  h  and  were 
centrifuged  at  3000  rpm  for  20  min.  The 
supernatant  layer  was  separated  and  added 
methanol  twice  in  volume  (5  ml).  The  contents 
were mixed well and again centrifuged at 3000 g 
for  20  min.  The  supernatant  layer  was  collected 
and  procedure  HPLC  analytical  procedure  was 
followed. The final volume was adjusted to 5 ml. 
The  quantitation  was  carried  out  using  external 
calibration curve. 
 
Determination of α-Keto Acids from Serum using 
Linear Calibration Curve with Spiked Sample 
 
Blood  sample  (5  ml)  collected  from  the 
diabetic patient was treated as determination of α-
Keto  acids  from  Serum.  The  serum  after 
deproteinization with methanol was divided in two 
equal parts. A part was treated as HPLC analytical 
procedure and other was added PYR (3 µg), KB (8 
µg), MKBA (6 µg), K3MVA (30 µg), KG (30 µg), 
K4MVA  (60  µg),  PPY  (40  µg),  and  procedure 
HPLC  was again  followed  the  final  volume  was 
adjusted  to  5  mL.  Quantitation  was  carried  out 
using  linear  calibration  and  increase  in  the 
response (average peak height / area) with added 
standard. 
 
Determination of α-Keto acids from Urine 
 
The  urine  (2  mL)  collected  from  the 
diabetic patients in Stoppard test tube (Quick fit) 
was  diluted  with  methanol  (1  mL)  and  was 
centrifuged  at  3000  rpm  for  20  min.  The  clear 
solution  was  transferred  to  volumetric  flask  and 
procedure HPLC was followed. The final volume 
was  adjusted  to  5  mL.  The  quantification  was 
carried out by calibration curve. 
 
Determination  of  α-Keto  acids  from  Urine  by 
Standard Addition 
 
The urine sample (2 mL) in duplicate from 
diabetic patient was treated as Determination of α-
Keto acids from Urine. A sample was processed as 
HPLC procedure and other was added PYR (2 µg), 
KB   (6 µg), MKBA (8 µg), K3MVA (40 µg), KG 
(30 µg), K4MVA (70 µg) and PPY (60 µg), again 
processed as HPLC procedure. The final  volume 
was adjusted to 5 ml. The quantitation was made 
by  linear  calibration  and  an  increase  in  the 
response with added standard. 
 
Results and Discussion  
Derivatization and Separation 
 
α-keto  acids  react  with  NPD  to  form 
nitroquinoxanol  derivatives  (Fig  1).  Nine  α-keto 
acids:  GA,  PYR,  KB,  MKBA,  K3MVA,  KG, 
K4MVA,  KHA,  and  PPY  were  treated  with      
NPD  separately  and  the  derivatives  formed       
were  extracted  in  chloroform,  and  examined  for 
elution from HPLC column. The effect of reaction 
conditions  such  as  pH,  amount  of  reagent  NPD 
added per analysis, warming time and temperature 
were  investigated.  The  reactions  were  initially 
monitored  by  a  UV-Vis  spectrophotometer.  The 
derivatives  showed  absorbance  maxima  in  the 
range of 299 to 340 nm against the reagent blank. 
The maxes obtained were considered for monitoring 
the reactions. The effect of pH within 1 to 10, at a 
unit interval  was  examined and the reaction  was 
observed maximum in acidic medium and acetate 
buffer (pH 3) was selected (Fig 2a). The reagent 
solution  (1%  w/v  in  methanol)  was  varied  from 
0.5-4.0 mL and at an interval of 0.5 mL. A similar 
response was observed with the addition of 1 mL 
and above and addition  of 1.5  mL  was selected. 
The warming time at 80 
0C was varied from 10-40 
min  at  an  interval  5  min.  Maximum  absorbance 
was observed  with  warming time  of 15  min and 
above and warming time of 30 min was selected 
(Fig  2b).  Each  of  the  derivatives  at  optimized 
conditions  obeyed  the  Beer’s  law  within  5-100 
µg/mL and did not show any change in absorbance 
up to 24 h.  Pak. J. Anal. Environ. Chem. Vol. 14, No. 1 (2013) 
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PYR = R = CH3 
KB = R = C2H5 
MKBA = R = (CH3)2 CH 
KG = R = CH2 . CH2 . COOH 
KHA = R = C4H9 
PPY = R = C6H5 . CH2 
K3MVA = R = CH3 . CH2 . CH – CH3 
K3 MVA = R = (CH3)2 CH . CH2 
 
Figure 1. Reaction of α-Keto acids with NPD.             
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. (a) Effect of pH (b) Effect of Temperature, Amount of 
reagent (1%, w/v) for the derivative of 2-oxo acids  with NPD. 
Conditions:  column Zorbax C-18 (4.6 x 150 mm id) isocratic elution 
with methanol – water – acetonitrile (42:56:2 v/v/v) with a flow rate 
of 0.9 ml /min. UV detection by photodiode array at 255 nm  
 
 
For  the  separation  and  simultaneous 
determination of the α-keto acids, a Zorbax C-18 
HPLC column was used. Each of the derivatives, 
eluted  as  a  single  peak  and  separated  from  the 
derivatizing reagent. For the separation  of the α-
keto  acids,  composition  of  the  mobile  phase 
solvents  was  changed.  An  isocratic  elution  with 
methanol:  water:  acetonitirle  (42:  56:  2,  v/  v/  v) 
with a flow rate of 0.9 mL/ min resulted a better 
resolution of GA PYR, KB, MKBA, K3MVA, KG, 
K4MVA,  KHA,  and  PPY  peaks.  Although  a 
baseline separation was achieved but excess of the 
derivatizing  reagent  affected  the  elution  of  GA 
derivative.  In  order  to  improve  the  separation  of 
GA concentration of the derivatizing reagent was 
decreased to 1 mL (Fig 3).  The peak identification 
was  based  on  the  retention  time  and  by  spiking 
each of the α-keto acids in sequence. Repeatability 
of the separation (precision) in terms of retention 
time  and  peak  height  was  examined  (n=5)  and 
relative standard deviations (RSD) were observed 
within  0.1-2.0%  and  1.5-2.9%,  respectively.  The 
derivatives absorb in the  UV region due to -* 
transition  within  quinoxalinols  rings.  The 
wavelength at peak maximum was examined with 
the diode-array detection at 255 nm. 
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Figure 3. HPLC separation of  (1) Reagent (2) GA (3) PYR (4) 
KB (5) MKBA, (6) K3MVA (7) KG (8) K4MVA (9) KHA and (10) 
PPY. Condition as Fig 2. 
 
 
Quantitation and Validation 
Linearity and limit of detection 
 
Linear calibration curves were obtained by 
recording average peak height/ peak area (n = 4) 
versus concentration of GA (0.2-5.0 µg/ mL), PYR 
(0.2-20  µg  /mL),  KB  (0.3-100  µg/  mL),  MKBA 
(0.45-100 µg/mL), KG (0.5-100 µg/ mL), K3MVA 
(0.6-100  µg/  mL),  K4MVA  (0.6-100  µg/  mL), 
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KHA  (0.7-100  µg/  mL),  PPY  (0.7-100  µg/  mL) 
with  coefficient  of  determination  (r
2)  ranging 
0.9953-0.9988.  The  limits  of  detection  (LOD) 
measured as three times the signal to noise ratio  
(3:1) were obtained within the range 0.05-0.26 µg/ 
mL and limit of quantitation (LOQ) measured as 
signal to noise ratio (10: 1) were within (0.15-0.8) 
µg/  mL  (Table1).  The  analysis  of  test  solutions    
(n = 6) of the mixture of the -keto acids indicated 
relative error within  0.1- 2.9%. 
 
Precision Recovery 
  
The derivatization reaction and separation 
was repeatable and reproducible and  variation  in 
the response (peak height/ peak area) of each of the 
α-keto acid was examined intra and inter day by 
the  same  operator  under  same  conditions  on  the 
same  day  and  different  days  (n  =  5)  and  RSDs 
were  observed  within  (0.3-2.8%)  and  (0.5-3.2%) 
respectively.  The  derivatives  were  found  to  be 
highly  stable  and  did  not  show  any  change  in 
response up to 48 h.  
 
The pharmaceutical preparations additives 
methylparabin,  propylparabin,  gum  acacia, 
manitol,  lactose,  fructose,  glucose,  galactose, 
sodium  chloride,  sodium  lacuryl  sulphate  and 
methyl  hydroxypropyl  cellulose  were  added  at 
least twice the concentration  of α-keto acids and 
analysis  was  carried  out  following  analytical 
procedure.  The  results  obtained  were  compared 
with  α-keto  acids  standards.  The  addition  of 
additives  did  not  affect  the  determination  as  the 
relative error was ± 2.9%. 
 
Sample Analysis 
 
A  pharmaceutical  preparation,  Ketostril 
tablet was analyzed for the contents of the -keto 
acids. The amounts of MKBA, K3MVA, K4MVA , 
and PPY found per tablet were 82.5 mg, 64.8 mg, 
98 mg, and 65.8 mg, with a RSD of 2.1%, 2.6%, 
2.2%  and  1.9%,  respectively.  The  values  found 
were  in  correlation  with  the  labeled  values  (per 
tablet)  of  86  mg,  67  mg,  101  mg,  and  68  mg, 
respectively. The analysis was also carried out by 
standard addition method by spiking the solutions 
of  the  drug  with  MKBA,  K3MVA,  K4MVA  and 
PPY.  The  amounts  found  correlated  with  the 
labeled values and % recovery was in the range of 
95.9-97%  with  RSD  between  0.91-2.02%  for 
MKBA, K3MVA, K4MVA and PPY. 
 
The  blood  samples  of  healthy  volunteers 
and  diabetic  patients  were  analyzed  for  the 
contents of α-Keto acids. Five healthy volunteers 
of 35-42 years age were subjected to test for blood 
glucose levels. The blood glucose levels measured 
at the day of sample collection were within 120-
140 mg/dL. The GA, PYR, KB, KG and K4MVA 
were detected in the concentration range of 0.234-
0.246  µg/mL,  0.166-0.175  µg/mL,  0.45-1.81 
µg/mL,  0.58-1.20  µg/mL  and  0.712-0.73  µg/mL 
RSD ranging between 0.3-2.6%.  
 
The blood samples of two volunteers were 
spiked with GA, PYR, KB, KG and K4MVA and 
amounts were found to correspond with the values 
evaluated  by  calibration  curve  (Table  2).  The  % 
recovery from the blood was 90 - 93% with RSD 
2.5%. The urine samples of five healthy volunteers 
with  blood  glucose  level  110-190  mg/  dL  were 
analyzed and the amounts of GA, PYR, KB, KG, 
K3MVA, and K4MVA found were within the range 
0.383-0.389 µg/ mL, 1.91- 2.93 µg/ mL, 1.51-1.82 
µg/ mL, 0.223-1.62 µg/ mL, 0.60-0.93 µg/ mL, and 
0.778-0.868  µg/  mL,  respectively,  with  RSD 
ranging 1.0-2.6 % (Table 2). Two urine samples 
were spiked with α-keto acids and analyses were 
again carried out. The results obtained correlated 
with that of direct calibration with recovery of α-
keto acids from the urine around 95%.   
 
Similarly  10  diabetic  patients  with  blood 
and urine  glucose level within 310- 450 mg/ L on 
the  day  of  sample  collection  were  analyzed  and  
PYR,  KB,  MKBA,  K3MVA  ,  KG,  K4MVA,  and 
PPY were found within 9.28-11.65 µg/ mL, 1.65- 
4.83 µg/ mL, 6.08-7.86 µg/ mL, 6.15-8.25 µg/ mL, 
5.19-7.81  µg/  mL,  7.34-7.84  µg/  mL  and  7.72- 
11.54 µg/ mL respectively with RSD ranging 0.19- 
3.2%  (Fig  4a)  (Table  3).  Among  these,  2  blood 
samples were also analyzed by standard addition. 
The  results  obtained  correlated  and  indicated  % 
recovery of 80%, 83%, 85%, 88%, 78%,  82%, and 
90%  for  PYR,  KB,  MKBA,  K3MVA,  KG, 
K4MVA, KHA, and PPY  with  RSD within 1.0- 
2.8, respectively. The urine samples of 10 diabetic 
patients with blood glucose levels within 310-480 
mg/  dL  indicated  the  α-keto  acids  PYR,  KB, 
MKBA,  K3MVA,  KG,  K4MVA  and  PPY  at  the Pak. J. Anal. Environ. Chem. Vol. 14, No. 1 (2013) 
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concentration  levels  9.32-14.36  µg/ml,  6.08-6.75 
µg/ml,  7.22-8.52  µg/ml,  5.58-8.34  µg/ml,  6.09-
10.98 µg/ mL, 12.06-12.56 µg/ml and 13.39-15.86 
µg/ml,  respectively  with  RSD  within  1.0-3.1%  
(Fig  4b).  Two  samples  were  also  analyzed    by 
standard addition and the amounts  of  α-keto acids 
found  agreed  with  calibration  procedure  and 
indicated recovery of  PYR, KB, MKBA, K3MVA, 
KG,  K4MVA    and  PPY    90.2%,    90%,    95%, 
88.4%,  82.6%,  85.4%,    87%,  respectively    with 
RSD of 0.9-1.9%, respectively The amount of -
keto  acids  observed  were  higher  in  diabetic 
patients  as  compared  healthy  volunteers.  The 
amount  of  -keto  acids  in  diabetic  patients 
correlated positively with blood glucose level with 
coefficient of determination and may be considered 
as markers for diabetic patients.       
 
Table 2. Quantitative analysis of α-Keto acids from Healthy blood and Urine person 
 
Sr. 
No. 
Age 
M= 
F= 
Glucose 
level 
mg/dl 
Random/ 
fasting 
Blood and 
Urine 
Samples 
GA 
µg/ml 
(n=6) 
(RSD) 
PYR  
µg/ml 
(n=6) 
(RSD) 
 
KB 
µg/ml 
(n=6) 
(RSD) 
 
KG 
µg/ml 
(n=6) 
RSD 
K3MVA 
µg/ml 
(n=6) 
(RSD) 
K4MVA µg/ml 
(n=6) 
(RSD) 
 
1  M/42  140  Blood  0.246 
(1.3) 
0.246 
(1.4)* 
0.233 
(1.6) 
0.233 
(1.1)* 
0.45 
(1.3) 
0.46 
(1.6)* 
0.88 
(1.3) 0.89 
(1.1) 
Nil 
 
0.725 
(1.1) 
0.7269 
(2.0)* 
2  M/40  130   
Blood 
0.234 
(1.4) 
0.234 
(1.3)* 
0.175 
(1.4) 
0.175 
(1.8)* 
0.61 
(0.1) 
0.61 
(2.0)* 
0.60 
(1.2) 
0.61 
(1.4) 
Nil 
 
 
 
0.629 
(1.4) 
0.628 
(1.8)* 
3  M/35  120   
Blood 
0.242 
(1.0) 
 
0.173 
(1.6) 
 
0.94 
(0.3) 
 
0.58 
(2.6) 
 
Nil 
 
0.73 
(2.6) 
 
4  F/40  135  Blood  0.238 
(2.0) 
0.178 
(1.3) 
0.96 
(0.3) 
0.89 
(2.1) 
Nil 
 
0.724 
(1.2) 
5  F/35  120  Blood  0.243 
(2.6) 
0.166 
(1.1) 
1.81 
(0.6) 
1.20 
(2.3) 
Nil 
 
0.712 
(1.2) 
6  F/30  190  Urine  0.389 
(1.6) 
0.390 
(1.8)* 
2.93 
(1. 2) 
2.94 
(2.4)* 
1.51 
(1.3) 
1.52 
(1.2) 
0.223 
(1.1) 
0.223 
(1.6) 
Nil 
0.78 
(1.1) 
0.78 
(1.4)* 
0.761 
(1.6) 
0.762 
(1.2)* 
7  F/35  170  Urine  0.385 
(1.3) 
2.88 
(1.1) 
1.55 
(1.8) 
0.62 
(0.9) 
0.60 
(1.3) 
0.802 
(1.0) 
8  M/40  160  Urine  0.383 
(1.2) 
0.384 
(1.6)* 
2.12 
(2.2) 
2.13 
(2.0)* 
1.82 
(1.4) 
1.82 
(1.3)* 
1.62 
(1.2) 1.62 
(1.8)* 
0.85 
(1.0) 
0.85 
(1.3)* 
0.778 
1.9) 
0.778 
(1.7)* 
9  M/35  130  Urine  0.384 (2.0)  2.44 
(1.3) 
1.66 
(1.1) 
1.60 (2.0)  0.93 
(1.8) 
0.863 
(2.2) 
10  M/38  110  Urine  Nil 
 
1.91 
(1.9) 
1.58 
(1.6) 
1.20 
(2.3) 
0.68 
(2.0) 
0.868 
(2.1) 
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Figure 4(a). HPLC responses of (1) Reagent (3) PYR (4) KB (5) 
MKBA, (6)  K3MVA  (7) KG (8) K4MVA (9) KHA and (10) PPY,    
From blood samples of diabetic patients Condition as Fig 2. 
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Figure 4(b).  HPLC separation of (1) Reagent (3) PYR (4) KB (5) 
MKBA (6) K3MVA (7) KG (8) K4MVA (9) KHA and (10) PPY.                                                     
after spiking HPLC Condition as Fig 2. 
 
Table 3. Quantitative analysis of α-Keto acids from Diabetic blood and Urine patients 
    
Sr. No. 
Age 
M= 
F= 
Blood 
Glucose 
level 
mg/dl 
Blood 
& 
Urine 
Sample 
PYR 
µg/ml 
(n=6) 
(RSD) 
KB 
µg/ml  
(n=6) 
(RSD) 
MKBA  
µg/ml 
(n=6) 
(RSD) 
K3MVA   
  µg/ml 
(n=6) 
(RSD) 
   KG  
µg/ml 
(n=6) 
(RSD) 
K4MVA  
µg/ml 
(n=6) 
     (RSD) 
PPY  
µg/ml 
(n=6) 
    (RSD) 
1  M/50  450   
Blood 
13.24 
(1.9) 
4.62 
(2.2) 
6.35 
(1.1) 
9.08 (2.6) 
 
8.16 (2.4) 
 
7.42 (3.0) 
 
12.06 
(2.2) 
2  M/45  440  Blood 
 
13.09 
(1.2) 
4.44 
(1.6) 
6.28 
(2.6) 
9.19 
(2.2) 
8.05 
(2.6) 
10.18 
(2.5) 
12.32 
(2.6) 
3  M/44  410  Blood 
 
12.65 
(1.9) 
4.52 
(2..2) 
5.98 
(2.8) 
8.42 
(2.5) 
7.35 
(1.9) 
7.32 
(2.2) 
1205 
(2.5) 
4  M/44  360  Blood 
 
12.48 
(2.0) 
4.19 
(2.5) 
5.65 
(2.2) 
8.66 
(1.9) 
6.26 
(3.0) 
7.22 
(2.4) 
11.26 
(2.9) 
5  M/43  360 
 
Blood 
 
 
12.39 
(1.6) 
12.39 
(1.2)* 
4.46 
(2.6) 
4.45 
(1.9)* 
5.48 
(2.4) 
5.48 
(1.2)* 
7.79 
(1.1) 
7.79 
(1.6)* 
6.86 
(2.2) 
6.85 
(2.9)* 
7.38 
(3.0) 
7.38 
(1.6)* 
11.84 
(2.9) 
11.84 
(1.4)* 
6  M/43  360  Blood 
 
12.81 
(1.6) 
3.55 
(1.9) 
5.88 
(2.2) 
7.22 
(1.3) 
6.09 
(2.9) 
7.48 
(1.4) 
11.16 
(2.5) 
7  M/40  310  Blood 
 
11.42 
(1.9) 
3.22 
(1.1) 
7.24 
(2.6) 
6.38 
(1.5) 
6.67 
(2.6) 
7.54 
(3.0) 
10.888 
(2.4) 
8  F/40  430  Blood 
 
10.42 
(1.3) 
2.96 
(1.9) 
6.62 
(2.2) 
5.94 
(2.5) 
6.34 
(2.2) 
7.72 
(1.1) 
9.16 
(2.4) 
9  F/38  400  Blood 
 
10.19 
(3.0) 
3.61 
(1.1) 
5.58 
(1.1) 
5.74 
(2.6) 
6.05 
(2.9) 
5.33 
(2.5) 
922 
(2.0) 
10  F/35  360  Blood 
 
10.08 
(2.6) 
3.32 
(1.8) 
5.26 
(2.2) 
5.27 
(3.0) 
6.16 
(2.4) 
5.38 
(2.1) 
8.45 
(2.5) 
11  M/48  440   
Urine 
16.42 
(1.1) 
6.82 
(1.9) 
8.65 
(2.0) 
9.28 
(2.1) 
10.62 
(2.5) 
10.09 
(2.5) 
19.22 
(2.6) 
12  M/45  440   
Urine 
16.26 
(2.8) 
6.85 
(1.9) 
8.19 
(3.0) 
9.46 
(2.1) 
10.24 
(1.6) 
10.72 
(2.9) 
18.64 
(3.0) 
13  M/44  410        
Urine 
15.35 
(2.2) 
6.84 
(1.6) 
8.28 
(2.4) 
9.02 
(1.2) 
10.14 
(2.4) 
10.44 
(2.8) 
16.38 
(2.2) 
14  M/44  360  Urine  15.62 
(2.4) 
5.95 
(1.9) 
7.92 
(2.8) 
9.36 
(2.4) 
10.82 
(1.1) 
10.28 
(2.6) 
18.44 
(2.82) 
15  M/43  360  Urine  15.12 
(2.2) 
5.35 
(1.1) 
7.26 
(1.5) 
8.24 
(2.4) 
10.36 
(2.6) 
10.46 
(2.5) 
16.72 
(2.9) 
16  M/43  360  Urine  15.12 
(2.6) 
5.45 
(1.6) 
7.75 
(1.1) 
8.18 
(2.6) 
11.29 
(1.1) 
10.04 
(2.9) 
16.28 
(1.2) 
17  M/40  410  Urine  15.53 
(1.9) 
525 
(2.4) 
7.67 
(3.0) 
8.35 
(2.4) 
11.08 
(1.1) 
10.16 
(2.2) 
16.36 
(2.6) 
18  M/40  330  Urine  15.58 
(2.6) 
5.72 
(2.2) 
7.95 
(2..9) 
8.72 
(2.8) 
11.42 
(2.6) 
10.82 
(2.8) 
16.44 
(2.2) 
19  M/38  400  Urine  14.72 
(2.2) 
5.48 
(1.9) 
8.16 
(2..9) 
6.42 
(2.9) 
10.36 
(2.6) 
10.72 
(1.9) 
16.22 
(2.4) 
20  M/35  360  Urine  14.54 
(2.5) 
5.75 
(1.9) 
8.28 
(2.2) 
6..36 
(2.5) 
10.22 
(2.2) 
10.96 
( 1.9) 
16.48 
(3.0) Pak. J. Anal. Environ. Chem. Vol. 14, No. 1 (2013) 
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Kieber and Mopper [1] have reported the 
separation  of  nine  -keto  acids  within  24  min. 
using o-phenylenediamine as dervatizing reagent, 
with  spectrofluorometric  detection  and  gradient 
elution. The present method enabled separation of 
nine  -keto  acids  within  14  min  with  more 
commonly  available  spectrophotometric  detection 
and isocratic elution.  
 
Conclusion 
 
In conclusion we have developed a highly 
sensitive  and  specific  method,  for  the 
determination  of  -keto  acids  using  NPD  as 
derivatizing  reagent.  Chromatographic  separation 
of nine -keto acids is performed at a flow rate 0.9 
mL/  min  at  255  nm  photodiode  array  detection, 
affording  good  separation  of  the  peaks,  good 
recoveries  and  shorter  retention  times  than  other 
techniques. The results for the analysis using the 
developed  method  for  four  -keto  acids  agreed 
with  the  labeled  values  in  pharmaceutical 
preparation.  -keto  acids  were  detected  and 
determined  quantitatively  from  blood  serum  and 
urine samples of diabetic patients (with metabolic 
disorders or suffering from various diseases) with 
RSD within 2.9 %. The blood and urine samples 
were also analyzed by standard addition. Both the 
results agreed with each other and the amounts of 
-keto  acids  found  were  higher  in  diabetic  than 
healthy volunteers.  
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